Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract

Urology

Volumn 53, Issue 3, 1999, Pages 510-515

  Pycha, Armin ^a   Grbovic, Marija ^a   Posch, Bernd ^a   Schnack, Beate ^a   Haitel, Andrea ^a   Heinz Peer, Gertraud ^a   Zielinski, Christoph C ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEUROTOXICITY; PRIORITY JOURNAL; REMISSION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINARY TRACT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 0033105237     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00543-3     Document Type: Article

References (32)

1. Otto T., Bex A., Krege S., et al. Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1). A clinical phase II study. Cancer. 80:1997;465-470.
2. Logothetis C.J., Dexeus F.H., Chong C., et al. Cisplatin, cyclophosphamid and doxorubicin chemotherapy in unresectable urothelial tumors: the M.D. Anderson experience. J Urol. 141:1989;33-37.
3. Sternberg C.N., Yagoda A., Scher H.I., et al. M-VAC (methotrexate, vinblastine, doxorubicine and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 139:1988;461-469.
4. Yagoda A. Chemotherapy of metastatic bladder cancer. Cancer. 45:1980;1879-1888.
5. Logothetis C.J., Samuels M.L., Ogden S., et al. Cyclophosphamide, doxorubicin and cisplatin for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol. 134:1985;460-464.
6. Harker WG, Meyers FJ, Freiha FS, et al, for the Northern California Oncology Group Study . Cisplatin, methotrexate and vinblastine (CMV) an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract . J Clin Oncol. 3:1985;1463-1470.
7. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 133:1985;403-407.
8. Loehrer P.J., Einhorn L.H., Elson P.H., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma a cooperative group study . J Clin Oncol. 10:1992;1066-1073.
9. Witjes J.A., Wullink M., Oosterhof G.O.N., et al. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol. 31:1997;414-419.
10. Skarlos DV, Aravantinos G, Linardou E, et al, for the Hellenic Co-operative Oncology Group Study . Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. Eur Urol. 31:1997;420-427.
11. McGuire W.P., Rowinsky E.K., Rosenheim N.B., et al. Taxol a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms . Ann Intern Med. 111:1989;273-279.
12. Holmes F.A., Walters R.S., Theriault R.L., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 83:1991;1797-1805.
13. Murphy W.K., Fossella F.V., Winn R.J., et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 85:1993;384-388.
14. Roth B.J., Dreicer R., Einhorn L.H., et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 12:1994;2264-2270.
15. Zielinski CH, Schnack B, Grbovic M, et al: Paclitaxel and carboplatin in patients with metastatic transitional cell carcinoma of the urothelium: results of a phase II trial. Br J Cancer (in press).
16. Calvert A.H., Newell D.R., Gumbell L.A. Carboplatin dosage prospective evaluation of a simple formula on renal function . J Clin Oncol. 7:1989;1748-1756.
17. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, and cisplatine for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 64:1989;2448-2458.
18. Chong C., Logothetis C.J., Dexeus F.H., et al. M-VAC as salvage chemotherapy in transitional cell carcinoma of the urothelium previously treated with cisplatin combination chemotherapy. Proc AACR. 28:1987;810.
19. Boutan-Laroze A., Mahjouhbi M., Droz J.P., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur J Cancer. 27:1991;1690-1694.
20. Igawa M., Ohkuchi T., Ueki T., et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin, and cisplatin for the treatment of advanced transitional cell carcinoma. J Urol. 144:1990;662-665.
21. Moore M.J., Tannock I.F., Ernst S.D., et al. Gemcitabine a promising new agent in the treatment of advanced urothelial cancer . J Clin Oncol. 15:1997;3441-3445.
22. Pollera C.F., Ceribelli A., Crecco M., et al. Weekly gemcitabine in advanced bladder cancer a preliminary report from a phase I study . Ann Oncol. 5:1994;182-184.
23. Stadler W.M., Kuzel T.M., Roth B., et al. Metastatic bladder cancer advances in treatment . J Clin Oncol. 15:1997;3394-3398.
24. Dreicer R., Gustin D.M., See W.A., et al. Paclitaxel in advanced urothelial carcinoma its role in patients with renal insufficiency and as salvage therapy . J Urol. 156:1996;1606-1608.
25. Papamichael D., Gallagher C.J., Oliver R.T.D., et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer. 75:1997;606-607.
26. Vaughn D.J., Malkowicz B.S., Zoltick B., et al. Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium. Semin Oncol. 24:1997;47-50.
27. Niell H.B., Rangel C., Miller A., et al. The activity of antimicrotubular agents in human bladder tumor cell lines (abstract). Proc AACR. 34:1993;202.
28. Adams J.D., Flora K.P., Goldspiel B.R., et al. Taxol a history of pharmaceutical development and current pharmaceutical concerns . Monogr Natl Cancer Inst. 15:1993;141-147.
29. Rowinsky E.K. Clinical pharmacology of taxol. Monogr Natl Cancer Inst. 15:1993;25-37.
30. Redman B.G., Smith D.C., Flaherty L., et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 16:1998;1844-1848.
31. Saxman S.B., Propert K.J., Einhorn B., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma a cooperative group study . J Clin Oncol. 15:1997;2564-2569.
32. Murphy B.A., Johnson D.R., Smith J., et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc ASCO. 15:1996;617.